Development history of boron delivery agents

Abstract

B (n, α) 7 Li capture reaction.

Bioorthogonal chemistry for prodrug activation in vivo

“…Within the dimensions of a single cell (approximately 5 to 9 mm), the a-particles and recoil 7 Li nuclei can deposit nearly all of their energy. 179 As a result, there is minimal risk of damage to the surrounding healthy tissue. Hence, 10 B agents can be considered as prodrugs of toxic a-particles in cancer treatment, with thermal neutrons as activators.…”

On Demand Degradable h-BN–Fe3O4 Nanocomposite Powders for BNCT Delivery Agents (Focused Mini-Review)

“…Boron-rich compounds and composites are of interest for the BNCT (Boron-Neutron-Capture-Therapy), which from last decade has been actively utilized for treatment of some types of aggressive cancers, where standard chemo-and more obvious radiation therapies reveal lowered efficacy (see e.g. [1][2][3][4]). Recent review [5] considering the BNCT in connection with next-generation boron drugs shows that this is a therapy with high LET (Linear Energy Transfer) facilitating the delivery of radiation targeted to tumor and almost sparing healthy cells by targeting 10 Bcontaining species to cancer ones.…”

Nanopowder Boron Compounds Doped with Ferromagnetic Clusters for BNCT

“…Boron compounds are of great interest for the Boron-Neutron-Capture-Therapy (BNCT), which from last decade has been actively utilized for treatment of several aggressive cancers, including locally invasive very malignant tumors such as melanoma, gliomas (cerebral glioblastoma multiform), recurrent head and neck, and triple negative breast cancers, where standard chemoand radiation therapies reveal their shortcomings [1][2][3][4].…”